tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Glaukos announces FDA approval of iDose TR NDA labeling supplement
PremiumThe FlyGlaukos announces FDA approval of iDose TR NDA labeling supplement
18d ago
Glaukos price target raised to $160 from $115 at Stifel
Premium
The Fly
Glaukos price target raised to $160 from $115 at Stifel
24d ago
Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors
Premium
Company Announcements
Glaukos Advances Phase 3 Glaucoma Implant Trial, Keeping GKOS in Focus for Investors
25d ago
Glaukos: Solid Fundamentals, Strong Multi-Segment Growth, and iDose Trajectory Support a Buy Rating Despite Near-Term Volatility
PremiumRatingsGlaukos: Solid Fundamentals, Strong Multi-Segment Growth, and iDose Trajectory Support a Buy Rating Despite Near-Term Volatility
1M ago
Glaukos Reports Strong Preliminary Q4 and 2025 Sales Growth
Premium
Company Announcements
Glaukos Reports Strong Preliminary Q4 and 2025 Sales Growth
1M ago
Glaukos sees Q4 revenue about $143M, consensus $129.46M
Premium
The Fly
Glaukos sees Q4 revenue about $143M, consensus $129.46M
1M ago
Glaukos price target raised to $145 from $115 at Stephens
PremiumThe FlyGlaukos price target raised to $145 from $115 at Stephens
1M ago
Glaukos price target raised to $145 from $140 at UBS
Premium
The Fly
Glaukos price target raised to $145 from $140 at UBS
2M ago
Glaukos price target raised to $145 from $120 at Truist
Premium
The Fly
Glaukos price target raised to $145 from $120 at Truist
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100